Pediatric-indicated home sleep apnea test for otherwise-healthy children aged 5-17 with suspected obstructive sleep apnea — business case

Intended use: For unattended recording of respiratory airflow, respiratory effort, oxygen saturation, pulse rate, and body position in the home, in children aged 5 through 17 years with clinical suspicion of obstructive sleep apnea and without neuromuscular disease, craniofacial syndrome, Down syndrome, sickle cell disease, obesity hypoventilation, or significant cardiopulmonary disease, for interpretation by a qualified sleep physician.

Who pays

• Writes the cheque: the ordering pediatric sleep practice or diagnostic sleep lab, which pays a net price per study to run and score the test claim 6unconfirmed — the file names this payer explicitly inside its TAM (total addressable market) component 2 figure, not as a separate claim. This is not a payer-reimbursement event at the point of purchase; the practice recovers the cost by billing its own payer mix afterward.
• Out of which budget line: outpatient diagnostic sleep testing, billed under CPT (Current Procedural Terminology) 95800/95801/95806 claim 1unconfirmed — a line that is **permanently unconfirmable in this repo**: CPT descriptors are AMA-licensed, check_cpt_code cannot return verified/refuted under any circumstance, and no HCPCS (Healthcare Common Procedure Coding System) alternative has been established either (hcpcs/payment/coverage all returned missing-cache unconfirmed on this build, matching the candidate's own record).
• Against which comparator: attended in-lab polysomnography. For children under 6, the file names CPT 95782/95783 as the comparator code claim 2unconfirmed. **For the rest of the 5-17 target band — the majority of the indication — no comparator code claim exists in the file at all.** This is a gap, not a finding; see "Where this case outruns the file."
• Stops buying instead: an in-lab pediatric PSG (polysomnography) bed-night, for the addressable share of referrals assumed to be waiting on one — TAM component 3 assumes 30-50% of pediatric PSG referral volume is currently waiting for an in-lab bed and would substitute claim 7unconfirmed. That figure itself rests on a further, unsourced premise that in-lab pediatric capacity is the rate limiter, which no claim in the file establishes.
• The payer who ultimately has to say yes: a commercial or Medicaid plan. The file's reimbursement claim asserts, in the load-bearing negative direction, that commercial and Medicaid medical policies generally do not cover home sleep apnea testing in patients under 18 claim 8unconfirmed. A second, conditional claim states that if that exclusion is real and if it is written as an age restriction rather than a device-clearance restriction, then FDA (US Food and Drug Administration) clearance alone does not unlock payment, and a policy-change campaign becomes a second, serial go-to-market cost claim 9unconfirmed.

The chain's weakest link is the payer, not the buyer. The practice-level transaction claim 6unconfirmed is a normal diagnostic-services purchase; what makes the chain fragile is that the file's own load-bearing reimbursement claim is an assertion of absence of coverage for exactly the population this candidate targets.

The money model

Decomposed into the three TAM components the candidate file itself names, not asserted as a market size.

The full decomposition now lives in the market model, which carries the chain, the six legs, and what each one rests on. Two of those legs have been filed as research rows rather than left as holes, so the reason this section cannot produce a number is now a work list with report_ids rather than a dead end. The rows below quote the legs this case needs; they do not restate the chain.

Read the largest figure first. It is the composite TAM, and it cannot be read at all — one of its three multiplicands has no number. That is a materially thinner starting point than a wrong-but-computable TAM; nothing in the file's money model is arithmetic yet, only inputs to an arithmetic that has not been performed.

State the market and adoption verdicts explicitly, run on this build:

• python3 -m connectors market "The pediatric HSAT segment (children aged 5-17 with suspected OSA) is a large enough addressable market to justify a dedicated device rather than an indication extension by an adult HSAT incumbent" → unverifiable — "Market-size claim (...) has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand." — the same question the candidate already asks and leaves open claim 20unconfirmed.
• python3 -m connectors adoption "A commercial or Medicaid payer will change a pediatric home-sleep-testing coverage policy on the strength of a cleared pediatric indication plus a published concurrent-PSG validation study" → unverifiable — "Adoption/preference claim (...) asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that — it needs primary research... Do NOT substitute a model's own estimate of stakeholder behaviour." — the same question the candidate already asks and leaves open claim 19unconfirmed.
• python3 -m connectors hcpcs G0399, payment G0399, coverage G0399, procedures 95782 (re-run on this build) → all unconfirmed, missing data/ caches — the same missing-file nulls the candidate's own Verifier pass already recorded. Nothing was searched; this is not evidence the codes are unpaid or the exclusion is real.

Path to first revenue

• First dollar comes from: the first ordering pediatric sleep practice or diagnostic lab purchasing or leasing the device/service at the assumed net price claim 6unconfirmed — a device/services sale into the diagnostic-testing channel, not a payer-reimbursement event. The payer's decision (claim 8unconfirmed/9) sets the ceiling on how many practices can afford to keep buying, not whether the first sale happens.
• What must exist first, each attributed:
  • Regulatory clearance via one of two routes the file itself leaves unresolved claim 3refuted — a 510(k) (premarket notification) against an adult HSAT predicate with the pediatric indication added claim 3refuted, or a De Novo (De Novo classification request) if FDA declines substantial equivalence on the grounds that pediatric event-scoring criteria differ from adult criteria claim 3refuted. The file's own refuted claim independently establishes that a pediatric-indicated predicate already exists — SNAP Diagnostics SAM Model 9-10000 claim 3refuted, cleared as K240100 (an FDA 510(k) clearance number) claim 3refuted, reading "Both pediatric and adult patients may be tested" claim 3refuted — refuted as read by the candidate (the premise that no such device exists is wrong), and the finding cuts toward the 510(k) branch being live claim 3refuted.
  • A billable code with a confirmed descriptor and a confirmed allowable — currently permanently unconfirmable claim 1unconfirmed.
  • Payer coverage resolved for the target age band — currently an asserted exclusion claim 8unconfirmed, with the added conditional that if the exclusion is age-based rather than clearance-based, clearance alone will not unlock it claim 9unconfirmed.
  • A validation study large enough to answer the file's own named dominant clinical risk — false negatives, because a cannula-and-belt montage without EEG cannot see arousals or normalise by true sleep time claim 11unconfirmed — sized by an explicitly unbenchmarked Generator estimate claim 12unconfirmed.
• Calendar to first dollar: 2-4 years claim 12unconfirmed to clearance and validation completion, before any device reaches a practice; a further, uncosted stretch if the payer-policy campaign in claim 9unconfirmed turns out to be real and necessary [assumption A3].
• Capital to first dollar: mid-single-digit millions claim 12unconfirmed, on an estimate the file itself states is unbenchmarked against any actual pediatric device study and that the De Novo branch would likely exceed [assumption A4]. This estimate does not include the payer-policy-campaign cost [assumption A3].

Routes

Four, laid out and not ranked. Choosing a commercial strategy is a Tier 3 act.

Route A — 510(k) fast-follower into the 12-17 band, sell into the existing diagnostic-testing channel

Build on the precedent the file's own Verifier pass surfaced: a pediatric-indicated MNR predicate already exists, and the WatchPAT family is already cleared to 12 years and older. Narrow the indication to the band with the most predicate cover, clear fastest, sell to ordering practices under the existing HSAT billing model.

• Requires: 510(k) clearance building on the pediatric-indicated predicate precedent claim 3refuted; a resolved billing code claim 1unconfirmed; a coverage resolution for the 12-17 slice specifically claim 8unconfirmed, claim 9unconfirmed.
• Costs: mid-single-digit millions and 2-4 years on the file's own unbenchmarked estimate claim 12unconfirmed, excluding the uncosted payer-policy-campaign leg [assumption A3].
• Killed by: FDA declines substantial equivalence for the pediatric population, on the grounds that pediatric hypopnea/AHI scoring criteria differ from adult criteria — the file itself rates this at least as likely as the 510(k) succeeding, per its own frontmatter device_class note.

Route B — De Novo into the 5-11 band, where no age-banded pediatric predicate has been found

The candidate's own Verifier residual: nothing found in the MNR clearance sweep covers ages 5-11 with an explicit age-banded pediatric OSA (obstructive sleep apnoea) indication. This route targets the whitespace that survives the refutation, at the cost of the harder regulatory branch.

• Requires: a De Novo grant; a prospective multi-site validation study with concurrent in-lab PSG as reference standard, sized to answer the false-negative risk in a lower-AHI, more-arousal-based population claim 11unconfirmed; no FTO (freedom to operate) claim currently exists in the file to clear before committing to this branch claim 25unconfirmed.
• Costs: the file's baseline estimate claim 12unconfirmed plus a De Novo premium in both capital and calendar that the file never quantifies [assumption A4].
• Killed by: the validation study fails to demonstrate acceptable sensitivity against concurrent in-lab PSG at pediatric AHI thresholds in the 5-11 band — the same failure mode the AASM's 2017 position paper already names as the professional society's standing objection to HSAT devices without CO2 or arousal detection claim 28verified.

Route C — License the validation dataset and scoring algorithm to an already-cleared incumbent

Sell the differentiator, not the device: the concurrent-PSG validation dataset and the pediatric scoring algorithm derived from it are the moat the file itself names claim 10unconfirmed. Licensing it into ResMed's or Itamar/ZOLL's already-cleared platform avoids building a device business at all.

• Requires: a validation dataset and algorithm built and defensible enough to license; a partner who believes the dose/scoring record is worth carrying claim 10unconfirmed; no FTO position currently exists on the algorithm itself claim 25unconfirmed.
• Costs: smaller capital outlay than build routes A or B — no fleet, channel, or billing-code build — but revenue becomes a royalty or transfer price, not a device price, and no figure in the file anchors that price [assumption A5].
• Killed by: an incumbent runs and completes its own pediatric validation independently rather than licensing — ResMed has already completed one adolescent HSAT-vs-PSG validation study (NCT03748771 (a ClinicalTrials.gov registration number), COMPLETED, 12-17 years, sponsor ResMed) claim 4unconfirmed, which the file's own moat analysis already flags as the single most consequential unresolved item against this asset claim 10unconfirmed.

Route D — Contract directly with pediatric sleep/ENT programs as a capacity-relief instrument, bypassing per-study payer billing

Sell into a hospital or health-system pediatric sleep program's capacity/throughput budget — where the value case is reducing the PSG referral backlog rather than winning a per-study reimbursement event — rather than through the ordinary diagnostic-billing channel this file's TAM otherwise assumes.

• Requires: hospital pediatric sleep/ENT programs willing to fund capacity relief directly; the assumption that families and clinicians would accept a home study in place of waiting for an in-lab bed claim 15unconfirmed; and, separately, that specialists will act on an unattended result for a surgical decision rather than requiring in-lab confirmation regardless claim 14unconfirmed, claim 18unconfirmed.
• Costs: the same clearance baseline as Route A or B claim 12unconfirmed, plus an unestablished hospital sales-cycle and contracting cost the file never addresses [assumption A3] to the extent it also depends on resolving the payer question in parallel.
• Killed by: pediatric sleep/ENT programs report, on internal audit, no referral-to- in-lab-bed delay large enough to justify a dedicated capacity-relief budget line — the file's only quantified wait-time evidence is non-US (a Québec adenotonsillectomy cohort) claim 32verified, so this route currently has no US-specific wait-time finding to stand on at all.

Assumption register

Every assumption cited above, with what would settle it and who could run it. These are written back to the candidate as unverified claims 34-38 via append_commercial_claims.py — an assumption that lives only in a business case is invisible to the Verifier.

Where this case outruns the file

• The composite TAM (C1 × C2 × C3) — not computable, because C1 (annual pediatric PSG referral volume) carries no stated number anywhere in the candidate file, and procedures returns a missing-cache null on top of a wrong-denominator problem (children 5-17 are essentially absent from Medicare FFS).
• Share of the addressable pool won by year 3 (A1) — no claim in the file addresses market share capture at all.
• Gross margin per test (A2) — no cost-of-goods, cloud-scoring, or support-cost data appears anywhere in the file.
• The payer-policy-change campaign's cost and calendar (A3) — claim 9unconfirmed states the campaign would exist as a second, serial cost if the coverage exclusion is age-based, but no figure in the file prices it.
• The De Novo branch's cost and calendar premium over the 510(k)-anchored estimate (A4) — claim 12unconfirmed is explicitly unbenchmarked and prices only the branch the estimate appears to assume, not the branch the file itself rates at least as likely.
• The licensing royalty or transfer price in Route C (A5) — Route C's entire revenue model has no figure anchoring it anywhere in the file.
• A comparator billing code for the bulk of the target population — the file names a comparator code (95782/95783) only for children under 6 claim 2unconfirmed; no claim addresses the comparator code for ages 6-17, which is most of the intended-use population.
• FTO/IP position — no claim in the file addresses freedom to operate, blocking patents, or expiry timelines at all claim 25unconfirmed, which every route above depends on to some degree (Routes B and C explicitly, on the algorithm and the device respectively).